本文選題：宮頸癌 + 宮頸癌前病變�。� 參考：《實(shí)用婦產(chǎn)科雜志》2017年02期

【摘要】：目的:探討Toll樣受體(TLRs)在宮頸人乳頭瘤病毒(HPV)16持續(xù)性感染及宮頸病變中的作用。方法:以PCR法檢測(cè)宮頸脫落細(xì)胞中TLR3、TLR7、TLR8、TLR9及干擾素β(IFN-β)基因在宮頸HPV16持續(xù)性感染及宮頸病變中的表達(dá),并分為HPV16持續(xù)感染組與HPV16非持續(xù)感染組及宮頸炎癥及CINⅠ組、高級(jí)別CIN和原位癌組、宮頸浸潤(rùn)癌組進(jìn)行比較分析。結(jié)果:1在HPV16持續(xù)感染組與HPV16非持續(xù)感染組中,TLR3 DNA表達(dá)量分別為0.622±0.160、0.696±0.155,干擾素β(IFN-β)DNA表達(dá)量分別為0.640±0.169、0.735±0.151,TLR3、IFN-βDNA在HPV16持續(xù)感染組表達(dá)量低于HPV16非持續(xù)感染組(t=6.574,P=0.011;t=4.378,P=0.038);TLR3 DNA與IFN-βDNA呈正相關(guān)(r=0.693,P0.001),TLR 9DNA與IFN-βDNA呈負(fù)相關(guān)(r=-0.384,P0.001)。2在宮頸炎癥及CINⅠ組、高級(jí)別CIN和原位癌組、宮頸浸潤(rùn)癌組中,TLR3DNA表達(dá)量分別為0.661±0.159、0.606±0.143、0.507±0.160,IFN-β表達(dá)量分別為0.722±0.169、0.659±0.144、0.483±0.143,TLR7DNA表達(dá)量為0.737±0.198、0.754±0.206、0.864±0.167,TLR9DNA表達(dá)量為0.531±0.172、0.606±0.192、0.701±0.200。TLR3、IFN-βDNA表達(dá)量隨宮頸病變進(jìn)展而逐漸下降(F=7.983,P0.001;F=12.163,P0.001),而TLR7、TLR9 DNA表達(dá)量則隨宮頸病變進(jìn)展而逐漸增高(F=3.647,P=0.028;F=9.415,P0.001)。結(jié)論:TLRs可能參與宮頸局部免疫系統(tǒng)對(duì)HPV16的清除過(guò)程,TLR3表達(dá)減低可能通過(guò)下調(diào)IFN-β表達(dá)而影響宮頸局部免疫功能,從而導(dǎo)致HPV16持續(xù)性感染。TLR3、TLR7、TLR9異常表達(dá)在宮頸病變發(fā)生及進(jìn)展中可能發(fā)揮重要作用。
[Abstract]:Objective: to investigate the role of Toll like receptor (TLRs) in persistent infection of cervical papillomavirus (HPV16) and cervical lesions. Methods: the expression of TLR3, TLR7, TLR8, TLLR9 and IFN- 尾 in cervical HPV16 persistent infection and cervical lesions were detected by PCR method. They were divided into HPV16 persistent infection group, HPV16 non-persistent infection group, cervix inflammation and CIN 鈪，

本文編號(hào)：1833368